圖 1. 上皮細胞可塑性的循環(huán)及誘導細胞 EMT 發(fā)生[1]。
A. 上皮細胞可以通過上皮-間充質轉化過程轉化為間充質細胞,在此期間上皮細胞失去了許多上皮特性,并具有間充質細胞的典型特性。在大多數生物發(fā)育的早期階段,上皮間質轉化 (EMT) 調控著重要的過程,在缺乏 EMT 的情況下,發(fā)育不能經過囊胚期。用 Matrix metalloproteinase-3 (C) 處理 SCp2 小鼠乳腺細胞 (B) 誘導 EMT。IWP-2 靶向結合 Porcupine ,Wnt 加工和分泌的抑制劑。 |
XAV939 Tankyrase 1 抑制劑,靶向 Axin,抑制 Wnt 信號傳導。 |
IWR-1 IWR-1是端錨聚合酶抑制劑,抑制Wnt/β-catenin信號傳導途徑。 |
SB-216763 ATP 競爭性的 GSK3 抑制劑。 |
ICG-001 結合 CREB 蛋白的 β-catenin/TCF 轉錄抑制劑。 |
MSAB MSAB 是 Wnt/β-catenin 信號傳導的有效和選擇性抑制劑。MSAB 與 β-catenin 結合,促進其降解,并下調 Wnt/β-catenin 靶基因。 |
NSC668036 Frizzled-Dvl 結構域抑制劑,阻斷 Wnt 信號。 |
Box5 Box5 是一種有效的 Wnt5a 拮抗劑。Box5 抑制 Wnt5a 信號并抑制 Wnt5a 介導的 Ca2+ 釋放。Box5 抑制細胞遷移。 |
TWS119 GSK-3β 抑制劑,激活 Wnt/β-catenin 通路。 |
SKL2001 SKL2001 是 Wnt/β-catenin 信號通路的激動劑,具有抗腫瘤活性。SKL2001 通過破壞 Axin/β-catenin 相互作用,穩(wěn)定細胞內 β-catenin。 |
[1] Thiery JP, et al. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006 Feb, 7(2):131-42.
[2] Bakir B, et al. EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol. 2020 Oct, 30(10):764-776.
[3] Yeung KT, et al. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017 Jan, 11(1): 28-39.
[4] Brabletz S, et al. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021 Sep 15, 40(18): e108647.
[5] Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995, 154(1): 8-20.
[6] Lei Y, et al. MicroRNAs target the Wnt/β‑catenin signaling pathway to regulate epithelial‑mesenchymal transition in cancer (Review). Oncol Rep. 2020 Oct, 44(4): 1299-1313.
[7] Qin K, et al. Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk. Genes Dis. 2023 Mar 24, 11(1): 103-134.
[8] Buyuk B, et al. Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis. Cell Mol Bioeng. 2021 Sep 2, 15(1): 1-13.
[9] Yu F, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021 Aug 30, 6(1): 307.
[10] Lecarpentier Y, et al. Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers. Front Oncol. 2019 Nov 18, 9: 1248.
[11] Zhu D, et al. hsa-miR-199b-3p suppresses osteosarcoma progression by targeting CCDC88A, inhibiting epithelial-to-mesenchymal transition, and Wnt/beta-catenin signaling pathway. Sci Rep. 2023 Aug 2, 13(1): 12544.
[12] Ling DJ, et al. MicroRNA-145 inhibits lung cancer cell metastasis. Mol Med Rep. 2015 Apr, 11(4): 3108-14.
[13] Qu J, et al. MicroRNA-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing Wnt/β-catenin/ZEB1 signaling. Int J Oncol. 2015 Dec, 47(6): 2141-52.
[14] Kang AR, et al. A novel RIP1-mediated canonical WNT signaling pathway that promotes colorectal cancer metastasis via β -catenin stabilization-induced EMT. Cancer Gene Ther. 2023 Jul 27.
[15] Zhou, et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition. Nat Cell Biol. 2004, 6: 931-940.
[16] Kaler P, et al. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene. 2009 Nov 5, 28(44): 3892-3902.
[17] Long X, et al. MRGBP promotes colorectal cancer metastasis via DKK1/Wnt/β-catenin and NF-kB/p65 pathways mediated EMT. Exp Cell Res. 2022 Dec 1, 421(1): 113375.